Madeleine Féquière

Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape. Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada. Communication regarding free trade agreements as they relate to the biopharmaceutical industry. The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Public Health Agency of Canada, regarding the federal response to the hepatitis C virus. Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Communications with Heath Canada regarding modernization of the medical devices regulatory framework. Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products. Communications with Health Canada regarding the application of its nitrosamine guidelines. Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials. Communications with Health Canada regarding guidelines for pediatric action plans. Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy. Communications regarding national pharmacare legislation, regulations, policies or programs. Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime. Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices. Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.

Arranging and participating in meetings on Canada's international competitivenes; potential trade/tariff barriers with the U.S. and Europe. Interacting with MPs, Senators, Ministers and government officials regarding funding/investment opportunities to expand Ferrero’s production facility in Brantford, Ontario Arranging and participating in meetings on regulatory modernization. Arranging and participating in meetings on food safety and agri-food. Arranging and participating in meetings on healthy eating and advertising.

Engaging government with respect to the importance of the Canada/US/Mexico Free Trade Agreement (CUSMA) to the life sciences sector & ensuring open supply chains to trade partners and tariff-free access to medical devices. Engaging with the Office of the Minister of Indigenous Services, Office of the Minister of Finance, Office of the Minister of Health, and Members of Parliament regarding the public reimbursement of Abbott brand products and Abbott's rapid diagnostic systems. Working with Food, Health & Consumer Products (FHCP) Infant Formula Council on the proposed regulatory modernization of Food & Drug Regulations Divisions 24 & 25.

Discussion about marketing Canadian Maintenance, Repair and Overhaul companies on international stage. Discussions about digital ID for travel in the global travel continuum. Discussion on government investment in infrastructure for remote and northern airports. Working with Transport Canada Aviation Security on Enhanced Security measures harmonizing with the Transportation Security Administration and Department of Homeland Security requirements. Working with the Public Health Agency of Canada (PHAC) ensuring the Orders in Council make operational sense in their requirements in keeping the travelling public safe during the COVID-19 pandemic. Also ensuring that the Transport Canada Aviation Security and Civil Aviation are harmonized in the issuance of Interim Orders which regulate the Aviation Industry during the pandemic. Status of European Union (EU) Bilateral - The Canadian Government and the European Union entered into Bilaterals. The issues are its impact on costs and trade to our industry. Request funding from CanExport Associations Program (CEA) International Marketing assistance from Global Affairs Canada with regard to Aircraft Maintenance, Repair and Overhaul (MRO) and Flight Training. Passenger Bill of Rights, Foreign Ownership, Joint Ventures and the possible cost impacts to our industry and unintended consequences. (Formerly known as Bill C-49 Transportation Modernization Act) Participation in the development of mitigation measures for the use of Ethylene Glycol and Halon and Greenhouse Gases with Environment and Climate Change Canada, and Transport Canada Participation in stakeholder consultation with Health Canada on regulatory matters with regard to public safety and costs to the industry. Obtain support from relevant government departments in dealing with the European Union Emissions Trading Scheme to ensure fairness to Canadian companies. International Student Program in respect of streamlining the process to obtain student study permits for commercial pilot training in Canada and provide exemptions on the caps for foreign aviation students. (Imagine Education au/in Canada Brand program) with Global Affairs Canada and Immigration, Refugees and Citizenship Canada. Government consultation (Transport Canada) with stakeholders on the privatization of CATSA and its impact on the industry and the cost to passengers. Acts to amend the Aeronautics Act and the Access to Information Act and to make consequential amendments to other Acts with regard to all sections, particularly the provisions enabling safety management systems and the protection of safety data from public dissemination. Federal jurisdiction at aerodromes as it pertains to noise responsibilities. We do not want the province/municipality to enforce noise around airports. We oppose attempts by provinces/municipalities from attempting to usurp the federal powers. The Federal Government regulation in this case refers to the Aeronautics Act. Excise Tax Act with regard to Reduction of Air Travellers Security Charge. Excise Tax Act with regards to the reduction of Aviation Fuel Taxes. Enhancement and growth of the Canadian Council for Aviation and Aerospace to cover all aviation human resource issues. Encouraging the implementation of Safety Management Systems throughout Canadian commercial aviation. Discussions with Transport Canada and Employment & Social Development Canada on removing barriers to entry for people who want to become pilots or aircraft maintenance engineers or technicians. Discussions with regard to the on-going management of the Air Carrier Security Measures (Document is classified). Discussions with Public Safety Canada regarding, and support for, actions to prevent Human Trafficking. Discussions on the Statutory Review of the Canada Transportation Act with respect to administerial advice on policies Discussions about restrictions (timelines, airspace and procedures onboard aircraft) in the context of special events with regards to public sa

strategic policy objectives for the MedTech sector regarding 2026 CUSMA review. export permits and export controls • Government investments in Artificial Intelligence (AI) compute infrastructure; • Government policy considerations on health data trust and privacy. Substances addressed in the third phase of the Chemicals Management Plan. Support from ISED, with respect to Strategic Innovation Fund Medical device cost recovery schemes with respect to filing fees Engage in pre-market and post-market regulatory requirements to ensure efficient and predictable processes that supports safety, effectiveness, quality, and Canada’s competitiveness in the medical device sector. Amendments to Copyright Act, regarding Technology Protection Measures (TPMs)